<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102375</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 7</org_study_id>
    <nct_id>NCT00102375</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer</brief_title>
  <official_title>Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the triple combination of Carboplatin,
      Paclitaxel and Topotecan has a superior clinical outcome in the treatment of ovarian cancer
      compared with the combination of Carboplatin and Paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carboplatin-Paclitaxel is the current standard in the first-line treatment of advanced
      ovarian cancer. One option to further improve the therapeutic results is the incorporation of
      a third, non-cross-resistant drug into first line chemotherapy of advanced ovarian cancer. In
      two separate, single center phase II studies, a different combination of the three active
      agents (Carboplatin, Paclitaxel and Topotecan) has been tested. In these studies, Carboplatin
      and Paclitaxel were given at standard doses and schedules, followed sequentially by Topotecan
      which was well tolerated at a dose of 1.25 mg/m2/day given for five days and repeated every
      21 days. The prolonged therapy is not associated with cumulative toxicity and the compliance
      of the patients was good.

      Study Hypothesis/Comparison: The triple combination (Carboplatin/Paclitaxel/Topotecan) yields
      superior outcome in the treatment of first-line ovarian cancer compared with the combination
      of Carboplatin + Paclitaxel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date>October 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <enrollment>900</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven epithelial carcinoma of the ovary or of the fallopian tube or
             extraovarian papillary serous carcinoma with extent to the ovary

          -  International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IV, regardless
             of measurable or non-measurable disease

          -  No prior chemo- or radiotherapy

          -  Adequate hematologic, renal and hepatic function:

               -  ANC ≥ 1.5 x 10^9/L,

               -  Platelet counts ≥ 100 x 10^9/L,

               -  Total bilirubin ≤ 1.5 x upper normal limit,

               -  Alkaline Phosphatase ≤ 3 x upper normal limit,

               -  Serum creatinine ≤ 1.25 upper normal limit,

               -  Estimated GFR ≥ 60 ml/min

          -  Performance status 0-2 (ECOG)

          -  Life expectancy must be greater than 12 weeks

        Exclusion Criteria:

          -  Non-epithelial tumors or mixed epithelial/non-epithelial tumors (e.g. mixed Mullerian
             tumors) or tumors of low malignant potential (borderline tumors)

          -  Prior treatment with chemo- or radiotherapy

          -  Administration of other simultaneous chemotherapeutic drugs or hormonal therapy or
             simultaneous radiotherapy during the study treatment period or planned whole abdominal
             radiotherapy

          -  History of congestive heart failure

          -  Symptomatic brain metastasis

          -  Complete bowel obstruction

          -  Dementia

          -  Active infection or other serious underlying medical condition

          -  Pre-existing motor or sensory neurologic pathology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobus Pfisterer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGO Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Hospital of the Medical Facilities RWTH</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Gynecology and Gyn. Oncology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus, Gynecological hospital</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Clinic of the Ernst-Moritz-Arndt-University</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecological Clinic of the Medical University</name>
      <address>
        <city>Hannover</city>
        <zip>30659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Gynecologic Hospital</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Schleswig-Holstein, Campus Kiel, Clinic for gynecology and obstetrics</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke University, University Gynecological Hospital</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital &quot;rechts der Isar&quot;</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Gynecology</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecological Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Gnyecology and gyn. Oncology HSK</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de</url>
    <description>Information on studies of the AGO-OVAR on Ovarian cancer</description>
  </link>
  <results_reference>
    <citation>Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45.</citation>
    <PMID>16882940</PMID>
  </results_reference>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2005</study_first_submitted>
  <study_first_submitted_qc>January 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2005</study_first_posted>
  <last_update_submitted>August 3, 2006</last_update_submitted>
  <last_update_submitted_qc>August 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2006</last_update_posted>
  <keyword>Ovarian Cancer</keyword>
  <keyword>first-line</keyword>
  <keyword>Topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

